Patrícia Rocha

Patrícia Rocha

Auto-generated profile, based on publicly available information

Patrícia Rocha

Department of Genetics, Portuguese Oncology Institute of Porto (IPO-Porto), Porto, Portugal

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2008 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
APAna Peixoto
Ana Peixoto
CSCatarina Gomes Rodrigues Santos
Catarina Gomes Rodrigues Santos
PRPatrícia Rocha
Patrícia Rocha
MPManuela Pinheiro
Manuela Pinheiro
SPSofia Príncipe
Sofia Príncipe
MTManuel R. Teixeira
Manuel R. Teixeira

14 August 2003 in Leukemia
Verified
Journal Article
Closed access
NCN Cerveira
N Cerveira
CCCecília Correia
Cecília Correia
Sofia DóriaSofia Dória
Sofia Dória
SBS Bizarro
S Bizarro
PRP Rocha
P Rocha
MTManuel R. Teixeira
Manuel R. Teixeira

26 October 2017 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
JGJoana Guerra
Joana Guerra
CPCarla Pinto
Carla Pinto
DPDiana Pinto
Diana Pinto
MPManuela Pinheiro
Manuela Pinheiro
RSRomina Silva
Romina Silva
MTManuel R. Teixeira
Manuel R. Teixeira
Despite all the knowledge already gathered, the picture of somatic genetic changes in colorectal tumorigenesis is far from complete. Recently, germline and somatic mutations in the exonuclease domain of polymerase epsilon, catalytic subunit (POLE) gene have been reported in a small subset of microsatellite‐stable and hypermutated colorectal carcinomas (CRCs), affecting the proofreading activity of the enzyme and leading to misincorporation of bases during DNA replication. To evaluate the role of POLE mutations in colorectal carcinogenesis, namely in advanced CRC, we searched for somatic mutations by Sanger sequencing in tumor DNA samples from 307 cases. Microsatellite instability and mutation analyses of a panel of oncogenes were performed in the tumors harboring POLE mutations. Three heterozygous mutations were found in two tumors, the c.857C>G, p.Pro286Arg, the c.901G>A, p.Asp301Asn, and the c.1376C>T, p.Ser459Phe. Of the POLE‐mutated CRCs, one tumor was microsatellite‐stable and the other had low microsatellite instability, whereas KRAS and PIK3CA mutations were found in one tumor each. We conclude that POLE somatic mutations exist but are rare in advanced CRC, with further larger studies being necessary to evaluate its biological and clinical implications.

1 April 2013 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JGJoana G Guedes
Joana G Guedes
IVIsabel Veiga
Isabel Veiga
PRPatrícia Rocha
Patrícia Rocha
PPPedro Pinto
Pedro Pinto
CPCarla Pinto
Carla Pinto
MTManuel R. Teixeira
Manuel R. Teixeira
Background: KRAS is an EGFR effector in the RAS/RAF/ERK cascade that is mutated in about 40% of metastatic colorectal cancer (mCRC). Activating mutations in codons 12 and 13 of the KRAS gene are the only established negative predictors of response to anti-EGFR therapy and patients whose tumors harbor such mutations are not candidates for therapy. However, 40 to 60% of wild-type cases do not respond to anti-EGFR therapy, suggesting the involvement of other genes that act downstream of EGFR in the RAS-RAF-MAPK and PI3K-AKT pathways or activating KRAS mutations at other locations of the gene. Methods: DNA was obtained from a consecutive series of 201 mCRC cases (FFPE tissue), wild-type for KRAS exon 2 (codons 12 and 13). Mutational analysis of KRAS (exons 3 and 4), BRAF (exons 11 and 15), and PIK3CA (exons 9 and 20) was performed by high resolution melting (HRM) and positive cases were then sequenced. Results: One mutation was present in 23.4% (47/201) of the cases and 3.0% additional cases (6/201) had two concomitant mutations. A total of 53 cases showed 59 mutations, with the following distribution: 44.1% (26/59) in KRAS (13 in exon 3 and 13 in exon 4), 18.6% (11/59) in BRAF (two in exon 11 and nine in exon 15) and 37.3% (22/59) in PIK3CA (16 in exon 9 and six in exon 20). In total, 26.4% (53/201) of the cases had at least one mutation and the remaining 73.6% (148/201) were wild-type for all regions studied. Five of the mutations we report, four in KRAS and one in BRAF, have not previously been described in CRC. BRAF and PIK3CA mutations were more frequent in the colon than in the sigmoid or rectum: 20.8% vs. 1.6% vs. 0.0% (P=0.000) for BRAF and 23.4% vs. 12.1% vs. 5.4% (P=0.011) for PIK3CA mutations. Conclusions: About one fourth of mCRC cases wild-type for KRAS codons 12 and 13 present other mutations either in KRAS, BRAF, or PIK3CA, many of which may explain the lack of response to anti-EGFR therapy observed in a significant proportion of these patients.

22 July 2010 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
APAna Peixoto
Ana Peixoto
CSCatarina Gomes Rodrigues Santos
Catarina Gomes Rodrigues Santos
MPManuela Pinheiro
Manuela Pinheiro
PPPedro Pinto
Pedro Pinto
MSMaria José Soares
Maria José Soares
MTManuel R. Teixeira
Manuel R. Teixeira

11 March 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JRJoao Ramalho-Carvalho
Joao Ramalho-Carvalho
MPMalini Pires
Malini Pires
SLSusana Lisboa
Susana Lisboa
IGInês Graça
Inês Graça
PRPatrícia Rocha
Patrícia Rocha
Carmen JeronimoCarmen Jeronimo
Carmen Jeronimo
MGMT downregulation in high-grade gliomas (HGG) has been mostly attributed to aberrant promoter methylation and is associated with increased sensitivity to alkylating agent-based chemotherapy. However, HGG harboring 10q deletions also benefit from treatment with alkylating agents. Because the MGMT gene is mapped at 10q26, we hypothesized that both epigenetic and genetic alterations might affect its expression and predict response to chemotherapy. To test this hypothesis, promoter methylation and mRNA levels of MGMT were determined by quantitative methylation-specific PCR (qMSP) or methylation-specific multiplex ligation dependent probe amplification (MS-MLPA) and quantitative RT-PCR, respectively, in a retrospective series of 61 HGG. MGMT/chromosome 10 copy number variations were determined by FISH or MS-MLPA analysis. Molecular findings were correlated with clinical parameters to assess their predictive value. Overall, MGMT methylation ratios assessed by qMSP and MS-MLPA were inversely correlated with mRNA expression levels (best coefficient value obtained with MS-MLPA). By FISH analysis in 68.3% of the cases there was loss of 10q26.1 and in 15% of the cases polysomy was demonstrated; the latter displayed the highest levels of transcript. When genetic and epigenetic data were combined, cases with MGMT promoter methylation and MGMT loss depicted the lowest transcript levels, although an impact in response to alkylating agent chemotherapy was not apparent. Cooperation between epigenetic (promoter methylation) and genetic (monosomy, locus deletion) changes affecting MGMT in HGG is required for effective MGMT silencing. Hence, evaluation of copy number alterations might add relevant prognostic and predictive information concerning response to alkylating agent-based chemotherapy.